Drugs in MeSH Category Histamine H1 Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs Inc	PROMETHAZINE HYDROCHLORIDE	promethazine hydrochloride	SUPPOSITORY;RECTAL	040479-001	Jun 24, 2003		DISCN	No	No
Bristol Myers Squibb	REMSED	promethazine hydrochloride	TABLET;ORAL	083176-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Impax Labs	CHLORPHENIRAMINE MALEATE	chlorpheniramine maleate	TABLET;ORAL	080809-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Amneal Pharms Ny	PROMETHAZINE HYDROCHLORIDE	promethazine hydrochloride	TABLET;ORAL	091179-001	Dec 13, 2010	AB	RX	No	No
Ivax Sub Teva Pharms	DIPHENHYDRAMINE HYDROCHLORIDE	diphenhydramine hydrochloride	CAPSULE;ORAL	080762-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Patent Landscape for NLM MeSH Class: Histamine H1 Antagonists

Last updated: April 23, 2026

What is the commercial market shape for H1 antihistamines?

Histamine H1 antagonists (MeSH) are a large, mature segment with strong generic penetration. Pricing power is primarily held by (1) branded second-generation agents with durable prescription share, and (2) the most recent pipeline entries that can differentiate on safety, pediatric dosing, formulation, or next-generation potency and selectivity. Off-patent oral tablets dominate unit volume in most markets, while specialty share concentrates in pediatrics, chronic allergic disease, and high-convenience delivery systems (ODT, melt, liquid, and nasal).

Market structure by product generation (typical dynamics)

Segment	Core drugs (examples)	Typical market driver	Patent relevance
1st-generation (sedating)	Diphenhydramine, chlorpheniramine	OTC access, low cost, short acting	Mostly off-patent; limited new IP via new salts/formulations
2nd-generation (non-sedating)	Loratadine, cetirizine, fexofenadine, desloratadine, levocetirizine	Allergy control with lower CNS effects	Many are off-patent in key markets; residual IP can come from formulations and new dosing
“Next-gen” differentiation	Newer enantiomers, sustained-release, combination products, novel formulations	Differentiated onset/duration, reduced pill burden, pediatric acceptability	IP tends to be driven by secondary patents and specific product presentations rather than new MOAs

How do market dynamics shift pricing and access?

Key demand drivers

• Seasonal allergic rhinitis drives recurring spikes in OTC and Rx demand.
• Chronic urticaria and allergic comorbidities support steady Rx use when patients require daily control.
• Pediatrics shifts product format preference toward liquid, dispersible, and weight-based dosing packs.
• Physician preference clusters around known safety profiles and long-duration dosing schedules.

Channel and reimbursement dynamics

• OTC vs Rx split determines how quickly price erosion follows loss of exclusivity.
• Formulary placement for second-generation agents remains concentrated on a small set of molecules.
• Generic substitution reduces post-launch monetization windows for new entrants unless they secure meaningful clinical or convenience differentiation.

Competitive behavior that matters for patent strategy

• Branded manufacturers increasingly defend economics through:
  • Switches to new formulations (ODT, extended release, combination packs)
  • Pediatric lifecycle strategies
  • Method-of-use patents that tie to narrow clinical endpoints
• Generic manufacturers target:
  • Bioequivalence and scalable manufacturing
  • Design-around via different salt forms or formulation routes where feasible

---

What does the patent landscape look like for H1 antagonists (MeSH class level)?

At the MeSH class level, the patent landscape is dominated by:

• Front-end composition-of-matter estates that largely matured decades ago for major molecules.
• Lifecycle patents that persist after primary molecule expiry through:
  • New polymorphs
  • New salts or hydrates
  • Specific formulations (extended release, ODT, suspension)
  • New dosing regimens (often pediatric-weight or renal-adjusted)
  • Combination products with additional actives (sometimes within adjacent therapeutic categories)

Patent landscape pattern (practical readout)

• For widely used H1 antagonists, primary IP has largely expired for most global markets.
• The remaining enforceable rights typically do not extend broad MOA monopoly; they are presentation- and indication-specific.
• Litigation risk clusters around:
  • Generic filing (ANDA/505(b)(2) in the US) against branded products with late-life formulation patents.
  • Compendial and label-driven use claims where a branded holder uses clinically anchored dosing language to defend method patents.

---

Where do major IP opportunities and risks sit?

Typical branded portfolio “defense zones”

Defense zone	What it protects	How generics try to work around
Formulation patents	Release profile, particle size, excipient matrix	Different delivery system or reformulation not covered by the claim
Salt/polymorph patents	Specific solid-state properties	Use alternate crystalline form and prove non-infringement
Method-of-use (narrow)	Defined dosing regimen and clinical context	Avoid the claimed regimen or use label not covered
Pediatric claims	Weight-based dosing and age-specific regimens	Different dosing schedule or non-covered submission path

Typical risk zones for product launches

• Late-life formulation patents can create hold-up even after molecule expiry.
• Anticipatory design-arounds matter more than generics relying solely on “same API, different manufacturer.”
• Generic entry timing is influenced by not only primary expiration but also by:
  • Unexpired formulation patents
  • Injunction history tied to specific product strengths
  • Jurisdiction-specific claim interpretations

---

Which IP metrics matter most for decision-making in this MeSH class?

Patent screening metrics (what to track in diligence)

• Patent family structure
  • Earliest priority date (composition claims)
  • Branches for formulation, polymorphs, and dosing
• Jurisdiction mapping
  • US granted patents vs EP validation and member-state status
  • China and other APAC filings for lifecycle enforcement
• Claim scope indicators
  • Whether claims recite process steps, particle attributes, or excipient systems
  • Whether claims are tied to label text, dosing intervals, or pharmacokinetic windows

Litigation and regulatory hooks that affect launch timing

• US paragraph IV events (where available) function as a strong signal for contested formulation or method patents.
• Orange Book listing (US) shows what patents a branded product lists against a specific NDC and strength.
• Key clinical trial linkage to late-life claims tends to show up in:
  • dosing studies for pediatric cohorts
  • renal impairment regimens
  • sustained-release performance claims

---

How should R&D teams interpret the MeSH scope for H1 antihistamines?

MeSH “Histamine H1 Antagonists” includes multiple drug entities and subclassifications. For patent analytics, the key practical point is scope breadth: it spans both classic antihistamines and modern non-sedating H1 blockers, meaning:

• The competitive set is large.
• Differentiation must be anchored to trial-supported claims and defensible formulation or regimen IP.
• “Generic substitution” will occur quickly for any product that does not protect beyond the molecule itself.

Practical R&D/IP implications

• New MOA within H1 is unlikely to be the default pathway; most economic pathways rely on:
  • formulation differentiation
  • dosing convenience
  • combination products
• Lifecycle strategy is therefore central even for new entrants.

---

What is the measurable exclusivity outlook when primary molecule patents expire?

Because most cornerstone H1 antihistamines are mature, the market generally transitions like this:

1. Molecule exclusivity runs out
2. Generic entry compresses margin
3. Branded firms shift to lifecycle IP
4. Late-life patents determine the remaining price premium window for specific presentations

In practical diligence, the exclusivity question becomes:
Which specific product presentation and label-driven dosing is still protected in the target market?

---

Key Takeaways

• The MeSH class “Histamine H1 Antagonists” is a mature, high-generic-penetration market where primary molecule patents largely define the past, not the future; current commercial differentiation is driven by formulation, dosing regimens, and pediatric or solid-state IP.
• Patent value in this space usually concentrates in secondary patents tied to specific product strengths, release profiles, salts/polymorphs, or narrow method-of-use claims.
• For R&D and investment decisions, the correct diligence unit is not the MeSH class or molecule alone; it is the specific defended product presentation and jurisdictional patent estate that can block or slow generic substitution.

---

FAQs

1. What type of patents most often remain enforceable for H1 antihistamines after molecule expiry?
   Formulation (release profile, excipient matrix), solid-state (polymorph/salt), and narrow method-of-use (dose regimen, patient subgroup) patents.

2. Why do H1 antihistamine markets often see fast margin compression?
   High substitutability, short clinical differentiation intervals, and rapid generic entry once primary molecule exclusivity expires.

3. What is the main strategic reason brands maintain lifecycle IP in this class?
   To defend premium pricing for specific presentations (e.g., pediatric-friendly formulations or sustained-release) even when the underlying molecule is generic.

4. What diligence artifacts best predict launch timing risk?
   Jurisdiction-mapped patent status by product NDC/strength, Orange Book-style listings (US), and identification of late-life patents tied to specific formulations and dosing language.

5. Does MeSH class scope help or hinder patent analysis for H1 antagonists?
   It helps to define the competitive universe, but it hinders precision; enforceability depends on the specific molecular product presentation and its secondary patents, not just the class label.

---

References (APA)

[1] National Library of Medicine. (n.d.). Histamine H1 antagonists. MeSH (Medical Subject Headings). https://www.nlm.nih.gov/mesh/